Egypt is routinely overlooked in favour of the GCC — and that is a strategic mistake. It is the largest Arab consumer market at over 110 million people, has aggressive localisation incentives designed to attract foreign manufacturers, and sits at the crossroads of Africa, Europe and the Middle East. For Indian pharmaceutical and chemical exporters with even modest global ambition, Egypt should be in the top five priority markets.
The consumer scale is real, but the strategic value is bigger than the consumer market alone. Egypt has actively positioned itself as a regional manufacturing hub through free-zone incentives (particularly around the Suez Canal Economic Zone), preferential trade agreements with the EU, Africa (AfCFTA) and the Arab world (GAFTA), and a government explicitly pursuing localisation of pharmaceutical and chemical production. An Indian manufacturer who establishes a formulation or secondary-packaging presence in Egypt can serve three continents from one footprint.
In pharmaceuticals, the Egyptian Drug Authority (EDA) has professionalised significantly in the last five years. Registration timelines have compressed to 12–18 months for imports and can be considerably shorter for local formulation partnerships. Indian companies are increasingly signing contract-manufacturing agreements with Egyptian formulators — the Indian company supplies APIs and know-how, the Egyptian partner runs the fill-finish and market-facing regulatory work, and the resulting product qualifies as locally manufactured for both public tenders and re-export.
Chemicals and packaging are under-supplied and structurally attractive. Construction chemicals, water-treatment chemicals, coatings, personal-care ingredients and eco-friendly packaging all show sustained import growth. The buyers are a mix of local industrials, multinationals with Egyptian operations (Unilever, P&G, PepsiCo, Nestlé) and export-oriented converters serving the EU. The formal buying culture, particularly among multinational subsidiaries, rewards quality documentation and regulatory transparency — an area where Indian mid-sized manufacturers can meaningfully outperform Chinese competition.
Entry through a local commercial agent is the standard play. Egyptian commercial agency law provides real legal protection to registered agents, so choose carefully — a bad agent is hard to remove. The agent should have documented sector experience (do not appoint a general trading house for a specialty product), a physical presence in Cairo and Alexandria at minimum, and the language capacity to engage EDA and buyer procurement teams in Arabic, English and French.
Payment terms and currency management deserve special attention. Egypt has periodically imposed foreign-exchange restrictions that make USD repatriation slow. The mitigations are well-known: price in USD with clear exchange-rate clauses, insist on confirmed LCs from top-tier Egyptian or GCC banks for early orders, and use freight-inclusive Incoterms (CFR Alexandria or CIF Damietta) to simplify the buyer's approvals.
The three-year path is coherent. Year 1 — enter through direct import via a strong commercial agent, target 6–10 SKUs with clear category fit. Year 2 — evaluate a formulation or secondary-packaging partnership with an Egyptian manufacturer to capture localisation benefits. Year 3 — use the Egyptian platform for structured re-export into Libya, Sudan, Jordan and selected sub-Saharan African markets under AfCFTA preferences. Very few Indian manufacturers have executed this sequence — the ones who do will hold a defensible position in North Africa and the Levant for the next decade.